2,275 results on '"Neuroendocrine Tumors diagnostic imaging"'
Search Results
2. [ 177 Lu]Lu-DOTATATE May Resensitize Neuroendocrine Tumors to Hormonal Therapy: Initial Clinical Experience in Renal Carcinoid.
- Author
-
Al-Ibraheem A, Abdlkadir A, Al-Adhami D, and Herrmann K
- Subjects
- Humans, Male, Female, Middle Aged, Octreotide analogs & derivatives, Octreotide therapeutic use, Organometallic Compounds therapeutic use, Kidney Neoplasms radiotherapy, Kidney Neoplasms diagnostic imaging, Carcinoid Tumor radiotherapy, Carcinoid Tumor diagnostic imaging, Neuroendocrine Tumors radiotherapy, Neuroendocrine Tumors diagnostic imaging
- Published
- 2024
- Full Text
- View/download PDF
3. A Novel PET Radiotracer for Detection of Neuroendocrine Tumors of the Lung and Prostate.
- Author
-
Gurbani S and Mao H
- Subjects
- Humans, Male, Positron Emission Tomography Computed Tomography methods, Prostatic Neoplasms diagnostic imaging, Neuroendocrine Tumors diagnostic imaging, Lung Neoplasms diagnostic imaging, Positron-Emission Tomography methods, Radiopharmaceuticals
- Published
- 2024
- Full Text
- View/download PDF
4. Models using comprehensive, lesion-level, longitudinal [ 68 Ga]Ga-DOTA-TATE PET-derived features lead to superior outcome prediction in neuroendocrine tumor patients treated with [ 177 Lu]Lu-DOTA-TATE.
- Author
-
Santoro-Fernandes V, Schott B, Deatsch A, Keigley Q, Francken T, Iyer R, Fountzilas C, Perlman S, and Jeraj R
- Subjects
- Humans, Male, Female, Middle Aged, Aged, Retrospective Studies, Treatment Outcome, Adult, Positron-Emission Tomography, Prognosis, Longitudinal Studies, Neuroendocrine Tumors diagnostic imaging, Neuroendocrine Tumors radiotherapy, Octreotide analogs & derivatives, Octreotide therapeutic use, Organometallic Compounds therapeutic use
- Abstract
Purpose: Somatostatin receptor (SSTR) imaging features are predictive of treatment outcome for neuroendocrine tumor (NET) patients receiving peptide receptor radionuclide therapy (PRRT). However, comprehensive (all metastatic lesions), longitudinal (temporal variation), and lesion-level measured features have never been explored. Such features allow for capturing the heterogeneity in disease response to treatment. Furthermore, models combining these features are lacking. In this work we evaluated the predictive power of comprehensive, longitudinal, lesion-level
68 GA-SSTR-PET features combined with a multivariate linear regression (MLR) model., Methods: This retrospective study enrolled NET patients treated with [177 Lu]Lu-DOTA-TATE and imaged with [68 Ga]Ga-DOTA-TATE at baseline and post-therapy. All lesions were segmented, anatomically labeled, and longitudinally matched. Lesion-level uptake and variation in uptake were measured. Patient-level features were engineered and selected for modeling of progression-free survival (PFS). The model was validated via concordance index, patient classification (ROC analysis), and survival analysis (Kaplan-Meier and Cox proportional hazards). The MLR was benchmarked against single feature predictions., Results: Thirty-six NET patients were enrolled and stratified into poor and good responders (PFS ≥ 25 months). Four patient-level features were selected, the MLR concordance index was 0.826, and the AUC was 0.88 (0.85 specificity, 0.81 sensitivity). Survival analysis led to significant patient stratification (p<.001) and hazard ratio (3⨯10-5 ). Lastly, in a benchmark study, the MLR modeling approach outperformed all the single feature predictors., Conclusion: Comprehensive, lesion-level, longitudinal68 GA-SSTR-PET analysis, combined with MLR modeling, leads to excellent predictions of PRRT outcome in NET patients, outperforming non-comprehensive, patient-level, and single time-point feature predictions., Message: Neuroendocrine tumor, peptide receptor radionuclide therapy, Somatostatin Receptor Imaging, Outcome Prediction, Treatment Response Assessment., (© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)- Published
- 2024
- Full Text
- View/download PDF
5. Maximum tumor diameter and renal function can predict the declining surface dose rate after 177 Lu-Dotatate: preliminary results of single institution in Japan.
- Author
-
Ono T, Ichikawa M, Tanada T, Kanezawa C, and Sato H
- Subjects
- Humans, Male, Female, Middle Aged, Prospective Studies, Aged, Japan, Adult, Neuroendocrine Tumors radiotherapy, Neuroendocrine Tumors diagnostic imaging, Tumor Burden, Radiopharmaceuticals therapeutic use, Kidney diagnostic imaging, Kidney pathology, Kidney Function Tests methods, Radiotherapy Dosage, Organometallic Compounds therapeutic use, Organometallic Compounds administration & dosage, Octreotide analogs & derivatives, Octreotide therapeutic use, Octreotide administration & dosage
- Abstract
Purpose: This study aimed to develop a user-friendly prediction formula for dose rate adjustment after initial
177 Lu-Dotatate therapy from a prospective observational study of patients., Materials and Methods: This study included consenting patients in a prospective observational study who underwent their first treatment in four cycles of177 Lu-Dotatate treatment at our hospital between January 2022 and February 2024. All patients received 7.4 GBq of177 Lu-Dotatate. The prediction formula was derived from the regression analysis of tumor-related factors and renal function. Creatinine clearance was estimated using the Cockcroft-Gault equation in this study for renal function., Results: Among the 13 patients (seven males, six females, median age: 59 years), logarithmically transformed total tumor volume (cc) and maximum tumor diameter (mm) of primary tumors or metastases showed strong correlations (p < 0.001, R2 = 0.897). As such, the maximum tumor diameter was used as the tumor parameter in the prediction formula. Additionally, maximum tumor diameter and creatinine clearance showed strong (p < 0.001, R2 = 0.768) and moderate (p = 0.013, R2 = 445) correlations, respectively, with the ratio of the dose rate 5.5-h post-administration to the dose rate immediately post-administration (%) at 1 m from the body surface. The resulting formula, 51.4 + 0.360 × maximum tumor diameter (mm) - 0.212 × creatinine clearance (ml/min), demonstrated an extremely strong correlation (p < 0.001, R2 = 0.937)., Conclusion: The present study showed that the maximum tumor diameter and renal function affected the declining the dose rate of patients surface after177 Lu-Dotatate, which can inform post-administration dose rate management and potentially facilitate outpatient treatment in Japan., (© 2024. The Author(s).)- Published
- 2024
- Full Text
- View/download PDF
6. Endoscopic ultrasound-guided radiofrequency ablation of pancreatic tumors.
- Author
-
Patel V, Abdelbaki A, Thosani NC, and Krishna SG
- Subjects
- Humans, Ultrasonography, Interventional methods, Neuroendocrine Tumors surgery, Neuroendocrine Tumors diagnostic imaging, Palliative Care methods, Pancreatic Neoplasms surgery, Pancreatic Neoplasms diagnostic imaging, Endosonography methods, Radiofrequency Ablation methods
- Abstract
Purpose of Review: Surgery is a cornerstone in the management of pancreatic cancer and precancerous pancreatic lesions. However, many patients are not suitable candidates for surgery at the time of diagnosis for various reasons. Endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) appears to be a promising treatment option for patients who are ineligible for surgery for management of pancreatic adenocarcinoma (PDAC), and pancreatic neuroendocrine tumors (PNETs), and pancreatic cystic lesions (PCLs)., Recent Findings: EUS-RFA may serve as an adjunct to chemotherapy or palliative measures for inoperable cases of PDAC. Given its feasibility and efficacy, EUS-RFA has an evolving niche as a minimally invasive and potentially definitive treatment for PNETs and high-risk PCLs such as intraductal papillary mucinous neoplasms (IPMNs). EUS-RFA is a generally well tolerated procedure, with abdominal pain and acute pancreatitis being the most common adverse effects, though the risk can be mitigated through prophylactic measures., Summary: There is an increasing body of evidence to support the use of EUS-RFA in managing pancreatic lesions, either as definitive, adjunctive, or palliative treatment, depending on lesion type., (Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
7. 177 Lu-DOTATATE Uptake in the Lungs of a Patient With COVID-19 Pneumonia.
- Author
-
Matsushita T, Otomi Y, Okada N, Kawanaka T, and Otsuka H
- Subjects
- Humans, Aged, Female, Pandemics, Single Photon Emission Computed Tomography Computed Tomography, Coronavirus Infections diagnostic imaging, Coronavirus Infections complications, Neuroendocrine Tumors diagnostic imaging, Neuroendocrine Tumors radiotherapy, COVID-19 diagnostic imaging, COVID-19 complications, Organometallic Compounds, Lung diagnostic imaging, Octreotide analogs & derivatives, Octreotide therapeutic use, Pneumonia, Viral diagnostic imaging, Pneumonia, Viral complications
- Abstract
Abstract: A 76-year-old woman with liver and bone metastasis of a duodenal neuroendocrine tumor received peptide receptor radionuclide therapy with 177 Lu-DOTATATE. Scintigraphy with SPECT/CT performed 4 days after the treatment demonstrated 177 Lu-DOTATATE uptake as multifocal ground glass opacities in the bilateral lungs. This uptake was considered to be due to COVID-19 pneumonia because the patient was infected with the virus 7 days prior to the treatment. The lung opacities became smaller, showing a decreased uptake, 2 months later, after the second treatment. 177 Lu-DOTATATE may be taken up during the active phase of COVID-19 pneumonia., Competing Interests: Conflicts of interest and sources of funding: none declared., (Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
8. Concomitant Pancreatitis and Pancreatic Neuroendocrine Tumor on MRI and 68 Ga-DOTATATE PET/CT.
- Author
-
Wang J and Kuker R
- Subjects
- Humans, Aged, Female, Organometallic Compounds, Positron Emission Tomography Computed Tomography, Neuroendocrine Tumors diagnostic imaging, Neuroendocrine Tumors pathology, Pancreatic Neoplasms diagnostic imaging, Pancreatic Neoplasms pathology, Magnetic Resonance Imaging, Pancreatitis diagnostic imaging
- Abstract
Abstract: A 66-year-old woman had an episode of pancreatitis with symptoms starting in October 2023. MRI showed an enhancing soft tissue mass along the superior border of the pancreatic body, as well as signal changes in the pancreatic body and the tail consistent with pancreatitis. The 68 Ga-DOTATATE PET/CT demonstrated intense radiotracer uptake within the peripancreatic soft tissue mass, significantly greater than the spleen background. Biopsy of this peripancreatic mass revealed well-differentiated grade 1 neuroendocrine tumor. The body and tail of the pancreas showed diffusely increased 68 Ga-DOTATATE uptake but obviously lower than the peripancreatic neuroendocrine tumor, consistent with pancreatitis., Competing Interests: Conflicts of interest and sources of funding: none declared., (Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
9. Pancreatic Neuroendocrine Neoplasm Concomitant with Branch-duct Intraductal Papillary Mucinous Neoplasm: A Case Report and Literature Review.
- Author
-
Sawai Y, Asada M, and Marusawa H
- Subjects
- Humans, Adenocarcinoma, Mucinous complications, Adenocarcinoma, Mucinous diagnostic imaging, Adenocarcinoma, Mucinous diagnosis, Adenocarcinoma, Mucinous surgery, Adenocarcinoma, Mucinous pathology, Neuroendocrine Tumors complications, Neuroendocrine Tumors diagnosis, Neuroendocrine Tumors diagnostic imaging, Neuroendocrine Tumors pathology, Neuroendocrine Tumors surgery, Male, Aged, Pancreatic Intraductal Neoplasms complications, Pancreatic Intraductal Neoplasms pathology, Pancreatic Intraductal Neoplasms diagnostic imaging, Pancreatic Intraductal Neoplasms diagnosis, Female, Endoscopic Ultrasound-Guided Fine Needle Aspiration, Neoplasms, Multiple Primary pathology, Neoplasms, Multiple Primary diagnostic imaging, Neoplasms, Multiple Primary surgery, Neoplasms, Multiple Primary diagnosis, Pancreatic Neoplasms complications, Pancreatic Neoplasms diagnostic imaging, Pancreatic Neoplasms diagnosis, Pancreatic Neoplasms pathology, Pancreatic Neoplasms surgery, Endosonography, Carcinoma, Pancreatic Ductal complications, Carcinoma, Pancreatic Ductal surgery, Carcinoma, Pancreatic Ductal diagnosis, Carcinoma, Pancreatic Ductal diagnostic imaging, Carcinoma, Pancreatic Ductal pathology
- Abstract
Reports of pancreatic neuroendocrine neoplasm (P-NEN) concomitant with intraductal papillary mucinous neoplasm (IPMN) are gradually increasing. However, many of these cases were diagnosed in the resected specimen incidentally. We herein report a case of minimal P-NEN concomitant with branch-duct IPMN that was successfully diagnosed preoperatively by contrast-enhanced endoscopic ultrasonography (EUS) and an EUS-guided fine-needle biopsy. These findings suggest that P-NEN as well as pancreatic ductal adenocarcinoma should be considered as concurrent tumors developing in patients with IPMNs. EUS is an essential modality when evaluating IPMN for detecting small lesions concomitant with IPMN.
- Published
- 2024
- Full Text
- View/download PDF
10. Intrapancreatic splenic tissue simulating neuroendocrine tumor.
- Author
-
Rama Alonso S, García-Talavera San Miguel P, Peñaherrera Cepeda AC, Campaña Díaz E, Badell Martínez JÁ, and Gómez-Caminero López F
- Subjects
- Humans, Diagnosis, Differential, Male, Positron Emission Tomography Computed Tomography, Female, Middle Aged, Choristoma diagnostic imaging, Neuroendocrine Tumors diagnostic imaging, Neuroendocrine Tumors pathology, Pancreatic Neoplasms diagnostic imaging, Pancreatic Neoplasms pathology, Spleen diagnostic imaging
- Published
- 2024
- Full Text
- View/download PDF
11. National practice patterns in the use of endoscopic ultrasound biopsy for resectable Pancreatic Neuroendocrine Tumors: Insights into the role of DOTATATE PET/CT in diagnosis.
- Author
-
Casey M, Brown A, Romero-Hernandez F, Wang JJ, Ganjouei AA, Tozzi F, Rashidian N, Kirkwood K, Corvera C, Nakakura E, Alseidi A, and Adam M
- Subjects
- Humans, Female, Male, Middle Aged, Aged, Endosonography statistics & numerical data, United States, Organometallic Compounds, Adult, Retrospective Studies, Positron Emission Tomography Computed Tomography statistics & numerical data, Neuroendocrine Tumors pathology, Neuroendocrine Tumors surgery, Neuroendocrine Tumors diagnostic imaging, Neuroendocrine Tumors diagnosis, Pancreatic Neoplasms pathology, Pancreatic Neoplasms surgery, Pancreatic Neoplasms diagnostic imaging, Practice Patterns, Physicians' statistics & numerical data, Practice Patterns, Physicians' trends
- Abstract
Introduction: Pancreatic neuroendocrine tumors (PNETs) are typically diagnosed using endoscopic ultrasound-guided (EUS) biopsy, which can be associated with complications. Since 2016, DOTATATE PET/CT has emerged as an effective tool to localize and stage PNETs., Methods: Patients with PNETs who underwent R0 resections were identified from the 2004-2019 National Cancer Database PUF. Joinpoint regression and multivariable logistic regression were used to analyze trends in the use of biopsy., Results: Of 16,746 R0 resected PNET patients, 44 % underwent diagnostic biopsy. Joinpoint regression showed a significant increase in the use of biopsy from 2004 to 2019 (APC 1.80, p < 0.001). A higher percentage of patients diagnosed after DOTATATE approval underwent biopsy compared to those diagnosed before (48 % vs. 42 %, p < 0.001). Adjusted analysis showed diagnosis after 2016 was associated with increased odds of biopsy (OR = 1.67, p < 0.001)., Conclusions: Despite technologic advancement with DOTATATE PET/CT, there has been a significant increase in the proportion of resectable PNETs undergoing preoperative biopsy., Competing Interests: Declaration of competing interest The authors report no conflicts of interest., (Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
12. A novel model for predicting postoperative liver metastasis in R0 resected pancreatic neuroendocrine tumors: integrating computational pathology and deep learning-radiomics.
- Author
-
Ma M, Gu W, Liang Y, Han X, Zhang M, Xu M, Gao H, Tang W, and Huang D
- Subjects
- Humans, Middle Aged, Male, Female, Aged, Adult, Multivariate Analysis, Postoperative Period, Prognosis, Tomography, X-Ray Computed, Radiomics, Deep Learning, Pancreatic Neoplasms pathology, Pancreatic Neoplasms diagnostic imaging, Pancreatic Neoplasms surgery, Liver Neoplasms pathology, Liver Neoplasms diagnostic imaging, Liver Neoplasms secondary, Liver Neoplasms surgery, Neuroendocrine Tumors pathology, Neuroendocrine Tumors surgery, Neuroendocrine Tumors diagnostic imaging, Nomograms
- Abstract
Background: Postoperative liver metastasis significantly impacts the prognosis of pancreatic neuroendocrine tumor (panNET) patients after R0 resection. Combining computational pathology and deep learning radiomics can enhance the detection of postoperative liver metastasis in panNET patients., Methods: Clinical data, pathology slides, and radiographic images were collected from 163 panNET patients post-R0 resection at Fudan University Shanghai Cancer Center (FUSCC) and FUSCC Pathology Consultation Center. Digital image analysis and deep learning identified liver metastasis-related features in Ki67-stained whole slide images (WSIs) and enhanced CT scans to create a nomogram. The model's performance was validated in both internal and external test cohorts., Results: Multivariate logistic regression identified nerve infiltration as an independent risk factor for liver metastasis (p < 0.05). The Pathomics score, which was based on a hotspot and the heterogeneous distribution of Ki67 staining, showed improved predictive accuracy for liver metastasis (AUC = 0.799). The deep learning-radiomics (DLR) score achieved an AUC of 0.875. The integrated nomogram, which combines clinical, pathological, and imaging features, demonstrated outstanding performance, with an AUC of 0.985 in the training cohort and 0.961 in the validation cohort. High-risk group had a median recurrence-free survival of 28.5 months compared to 34.7 months for the low-risk group, showing significant correlation with prognosis (p < 0.05)., Conclusion: A new predictive model that integrates computational pathologic scores and deep learning-radiomics can better predict postoperative liver metastasis in panNET patients, aiding clinicians in developing personalized treatments., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
13. Distinguishing Pituitary Metastasis and Pituitary Neuroendocrine Tumors through Conventional MR Imaging and Clinical Features.
- Author
-
Yuzkan S, Erkan B, Dogukan FM, Ozkiziltan U, Balsak S, Arslan FZ, Tutuncuoglu B, Arikan CC, Karatay H, Akpinar E, Ertan Y, Hatipoglu E, Eraslan C, Kitis O, Calli C, and Kocak B
- Subjects
- Humans, Female, Male, Middle Aged, Retrospective Studies, Diagnosis, Differential, Adult, Aged, Sensitivity and Specificity, Pituitary Neoplasms diagnostic imaging, Pituitary Neoplasms secondary, Pituitary Neoplasms pathology, Magnetic Resonance Imaging methods, Neuroendocrine Tumors diagnostic imaging, Neuroendocrine Tumors pathology
- Abstract
Background and Purpose: Given their overlapping features, pituitary metastases frequently imitate pituitary neuroendocrine tumors in neuroimaging studies. This study aimed to distinguish pituitary metastases from pituitary neuroendocrine tumors on the basis of conventional MR imaging and clinical features as a practical approach., Materials and Methods: In this 2-center retrospective study, backward from January 2024, preoperative pituitary MR imaging examinations of 22 pituitary metastases and 74 pituitary neuroendocrine tumors were analyzed. Exclusion criteria were as follows: absence of a definitive histopathologic diagnosis, history of pituitary surgery or radiation therapy before MR imaging, and pituitary neuroendocrine tumors treated with medical therapy. Two radiologists systematically evaluated 13 conventional MR imaging features that have been reported more commonly as indicative of pituitary metastases and pituitary neuroendocrine tumors in the literature. Age, sex, history of cancer, and maximum tumor size constituted the clinical/epidemiologic features. The primary cancer origin for this study was also noted. Univariable and multivariable logistic regression was used for the selection of variables, determining independent predictors, and modeling. Interobserver agreement was evaluated for all imaging parameters using the Cohen κ statistic or intraclass correlation coefficient., Results: A total of 22 patients with pituitary metastases (8 women; mean age, 49.5 [SD, 13] years) and 74 patients with pituitary neuroendocrine tumors (36 women; mean age, 50.1 [SD, 11] years) were enrolled. There was no statistically significant distributional difference in age, sex, or maximum tumor size between the 2 groups. Lung cancer (9/22; 41%) was the most commonly reported primary tumor, followed by breast (3/22; 13.6%) and unknown cancer (3/22; 13.6%). Logistic regression revealed 3 independent predictors: rapid growth on control MR imaging, masslike or nodular expansion of the pituitary stalk, and a history of cancer. The model based on these 3 features achieved an area under the curve, accuracy, sensitivity, specificity, and Brier score of 0.987 (95% CI, 0.964-1), 97.9% (95% CI, 92.7%-99.8%), 95.5% (95% CI, 77.2%-99.9%), 98.6% (95% CI, 92.7%-100%), and 0.025, respectively., Conclusions: Two conventional features based on pituitary MR imaging with the clinical variable of history of cancer had satisfying predictive performance, making them potential discriminators between pituitary metastases and pituitary neuroendocrine tumors. In cases in which differentiation between pituitary metastases and pituitary neuroendocrine tumors poses a challenge, the results of this study may help with the diagnosis., (© 2024 by American Journal of Neuroradiology.)
- Published
- 2024
- Full Text
- View/download PDF
14. Clinical impact of using [ 18 F]AlF-NOTA-octreotide PET/CT instead of [ 68 Ga]Ga-DOTA-SSA PET/CT: Secondary endpoint analysis of a multicenter, prospective trial.
- Author
-
Leupe H, Pauwels E, Vandamme T, Van den Broeck B, Lybaert W, Dekervel J, Van Herpe F, Jaekers J, Cleeren F, Hofland J, Brouwers A, Koole M, Bormans G, Van Cutsem E, Geboes K, Laenen A, Verslype C, Stroobants S, and Deroose CM
- Subjects
- Humans, Male, Middle Aged, Female, Aged, Prospective Studies, Adult, Octreotide analogs & derivatives, Radiopharmaceuticals, Somatostatin analogs & derivatives, Organometallic Compounds, Gallium Radioisotopes, Neoplasm Staging methods, Positron Emission Tomography Computed Tomography methods, Neuroendocrine Tumors diagnostic imaging, Neuroendocrine Tumors pathology
- Abstract
[
18 F]AlF-NOTA-octreotide ([18 F]AlF-OC) is a promising alternative for [68 Ga]Ga-DOTA-somatostatin analogs (SSAs) in positron emission tomography (PET) imaging of the somatostatin receptor (SSTR). Our aim is to assess changes in TNM staging and differences in patient management between [18 F]AlF-OC PET/CT and [68 Ga]Ga-DOTA-SSA PET/CT in the work-up of neuroendocrine tumor (NET) patients. Patients who underwent both [18 F]AlF-OC and [68 Ga]Ga-DOTA-TATE or [68 Ga]Ga-DOTA-NOC PET/CT in our multicenter study (Pauwels et al., J Nucl Med.2023;63:632-638) with a NET were included for analysis. TNM staging was determined and compared for both tracers. For each patient, the blinded [68 Ga]Ga-DOTA-SSA or [18 F]AlF-OC PET/CT images were presented in random order at a multidisciplinary team board. The images were presented together with clinical information and compared with previous SSTR and [18 F]FDG PET/CT imaging. After a consensus decision for patient management was recorded, the board was presented with the PET/CT images from the other SSTR tracer and a decision was made for the second tracer. Differences in management were classified as major if it entailed an intermodality change and minor if it led to an intramodality change. Compared with [68 Ga]Ga-DOTA-SSA, the use of [18 F]AlF-OC led to a change in 16/75 patients: TNM staging changes in 10/75 patients (13.3%; downstaging in 3/10, upstaging in 7/10) and differences in clinical management were seen in 10/75 patients (13.3%), leading to a major difference in 7/10 cases and a minor change in 3/10 cases. All 10 cases with a difference in patient management between both PET tracers were caused by additional lesion detection by [18 F]AlF-OC. The use of [18 F]AlF-OC did not impact TNM staging or clinical management in the large majority of the patients (86.7%), further validating the potential for routine clinical use of [18 F]AlF-OC PET/CT as an alternative for [68 Ga]Ga-DOTA-SSA PET/CT. The trial is registered under ClinicalTrials.gov identifier NCT04552847 and EudraCT 2020-000549-15., (© 2024 British Society for Neuroendocrinology.)- Published
- 2024
- Full Text
- View/download PDF
15. Metabolic Tumor Volume on 18-Fluorodeoxyglucose Positron Emission Tomography as a Prognostic Marker of Survival in Patients With Locally Advanced or Metastatic Neuroendocrine Neoplasms Treated With 177Lutetium-DOTA-Octreotate Peptide Receptor Radionuclide Therapy.
- Author
-
De Silva MK, Chan DLH, Bernard EJ, Conner AJ, Mascall SL, Bailey DL, Roach PJ, Clarke SJ, Diakos CI, Pavlakis N, and Schembri G
- Subjects
- Humans, Male, Middle Aged, Female, Retrospective Studies, Aged, Prognosis, Adult, Receptors, Peptide metabolism, Glycolysis, Aged, 80 and over, Pancreatic Neoplasms pathology, Pancreatic Neoplasms radiotherapy, Pancreatic Neoplasms diagnostic imaging, Pancreatic Neoplasms mortality, Progression-Free Survival, Treatment Outcome, Neuroendocrine Tumors pathology, Neuroendocrine Tumors radiotherapy, Neuroendocrine Tumors diagnostic imaging, Neuroendocrine Tumors metabolism, Neuroendocrine Tumors mortality, Fluorodeoxyglucose F18, Octreotide analogs & derivatives, Octreotide therapeutic use, Radiopharmaceuticals, Positron-Emission Tomography methods, Tumor Burden, Organometallic Compounds therapeutic use
- Abstract
Objective: We investigated metabolic tumor volume (MTV) and total lesion glycolysis (TLG) on pre-treatment FDG-PET as prognostic markers for survival in patients with metastatic neuroendocrine neoplasms (NENs) receiving peptide receptor radionuclide therapy (PRRT)., Methods: A retrospective review of patients with metastatic NENs receiving PRRT was undertaken. Pre-treatment FDG-PET images were analyzed and variables collected included MTV and TLG (dichotomized by median into high vs low). Main Outcomes were overall survival (OS) and progression-free survival (PFS) by MTV and TLG (high vs low)., Results: One hundred five patients were included. Median age was 64 years (50% male). Main primary NEN sites were small bowel (43.8%) and pancreas (40.0%). Median MTV was 3.8 mL and median TLG was 19.9. Dichotomization formed identical cohorts regardless of whether MTV or TLG were used. Median OS was 72 months; OS did not differ based on MTV/TLG high versus low (47.4 months vs not reached; hazard ratio, 0.43; 95% confidence interval [CI], 0.18-1.04; P = 0.0594). Median PFS was 30.4 months; PFS differed based on MTV/TLG high versus low (21.6 months vs 45.7 months; hazard ratio, 0.35; 95% CI, 0.19-0.64; P = 0.007)., Conclusions: Low MTV/TLG on pre-treatment FDG-PET was associated with longer PFS in metastatic NEN patients receiving PRRT., Competing Interests: The authors declare no conflict of interest., (Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
16. Defining the optimal segmentation method for measuring somatostatin receptor expressing tumor volume on 68 Ga-DOTATATE positron emission tomography/computed tomography to predict prognosis in patients with gastroenteropancreatic neuroendocrine tumors.
- Author
-
Filizoglu N, Ozguven S, Akin Telli T, Ones T, Dede F, Turoglu HT, and Erdil TY
- Subjects
- Humans, Male, Female, Middle Aged, Prognosis, Adult, Aged, Image Processing, Computer-Assisted methods, Retrospective Studies, Aged, 80 and over, Neuroendocrine Tumors diagnostic imaging, Neuroendocrine Tumors metabolism, Neuroendocrine Tumors pathology, Positron Emission Tomography Computed Tomography, Receptors, Somatostatin metabolism, Pancreatic Neoplasms diagnostic imaging, Pancreatic Neoplasms metabolism, Pancreatic Neoplasms pathology, Organometallic Compounds, Intestinal Neoplasms diagnostic imaging, Intestinal Neoplasms metabolism, Intestinal Neoplasms pathology, Stomach Neoplasms diagnostic imaging, Stomach Neoplasms metabolism, Stomach Neoplasms pathology, Tumor Burden
- Abstract
Objective: We aimed to compare different segmentation methods used to calculate prognostically valuable volumetric parameters, somatostatin receptor expressing tumor volume (SRETV), and total lesion somatostatin receptor expression (TLSRE), measured by 68 Ga-DOTATATE PET/CT and to find the optimal segmentation method to predict prognosis., Patients and Methods: Images of 34 patients diagnosed with gastroenteropancreatic neuroendocrine tumor (GEPNET) who underwent 68 Ga-DOTATATE PET/CT imaging were reanalyzed. Four different threshold-based methods (fixed relative threshold method, normal liver background threshold method, fixed absolute standardized uptake value (SUV) threshold method, and adaptive threshold method) were used to calculate SRETV and TLSRE values. SRETV of all lesions of a patient was summarized as whole body SRETV (WB-SRETV) and TLSRE of all lesions of a patient was computed as whole body TLSRE (WB-TLSRE)., Results: WB-SRETVs calculated with all segmentation methods were statistically significantly associated with progression-free survival except WB-SRETV at which was calculated using adaptive threshold method. The fixed relative threshold methods calculated by using 45% (WB-SRETV 45% ) and 60% (WB-SRETV 60% ) of the SUV value as threshold respectively, were found to have statistically significant highest prognostic value (C-index = 0.704, CI = 0.622-0.786, P = 0.007). Among WB-TLSRE parameters, WB-TLSRE 35% , WB-TLSRE 40% , and WB-TLSRE 50% had the highest prognostic value (C-index = 0.689, CI = 0.604-0.774, P = 0.008)., Conclusion: The fixed relative threshold method was found to be the most effective and easily applicable method to measure SRETV on pretreatment 68 Ga-DOTATATE PET/CT to predict prognosis in GEPNET patients. WB-SRETV 45% (cutoff value of 11.8 cm 3 ) and WB-SRETV 60% (cutoff value of 6.3 cm 3 ) were found to be the strongest predictors of prognosis in GEPNET patients., (Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
17. False-Negative Neuroendocrine Tumor Identified With 68 Ga-DOTATOC PET/CT : A Case of Well-Differentiated Somatostatinoma.
- Author
-
Moreau A, Chaouat C, Walter T, Dupré A, and Kryza D
- Subjects
- Humans, Male, Adult, False Negative Reactions, Neuroendocrine Tumors diagnostic imaging, Neuroendocrine Tumors pathology, Positron Emission Tomography Computed Tomography, Organometallic Compounds, Octreotide analogs & derivatives, Somatostatinoma diagnostic imaging
- Abstract
Abstract: We report the case of a 25-year-old man who was undergoing follow-up for neurofibromatosis type 1. The man underwent 68 Ga-DOTATOC PET/CT for a suspected well-differentiated duodenal neuroendocrine tumor. This examination did not reveal any significant uptake, whereas complementary 18 F-FDG PET/CT showed moderate 18 F-FDG uptake in the primary tumor as well as the adenopathy. Histology, a well-differentiated duodenal neuroendocrine tumor was confirmed, consistent with the diagnosis of somatostatinoma. Although rare, this well-differentiated neuroendocrine tumor should be kept in mind as a possible source of false-negative somatostatin receptor PET/CT findings., Competing Interests: Conflicts of interest and sources of funding: none declared., (Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
18. [Nuclear medicine approaches in the diagnosis and treatment of neuroendocrine neoplasms].
- Author
-
Kaletsch M, Pfestroff A, and Luster M
- Subjects
- Humans, Nuclear Medicine methods, Radiopharmaceuticals therapeutic use, Receptors, Somatostatin, Somatostatin analogs & derivatives, Somatostatin therapeutic use, Neuroendocrine Tumors diagnostic imaging, Neuroendocrine Tumors therapy
- Abstract
Despite, or perhaps because of the rarity of neuroendocrine neoplasms, the diagnosis and treatment of these malignancies is of particular importance. Nuclear medicine can make an important contribution to this challenge. It offers the most sensitive and specific imaging of these tumor entities and can be helpful in treatment due to the radiotherapeutic drugs that have recently been approved. This theragnostic (fusion of therapeutic and diagnostic) concept is based on the frequent overexpression of somatostatin receptors on neuroendocrine tumor cells.Using diagnostic and therapeutic pharmaceuticals based on analogues from somatostatin, most applications from the nuclear medicine are successful, an additional therapeutic method is SIRT, also known as TARE, in which the hypervascularization of NEN-metastases is used as a therapeutic target., Competing Interests: Die Autorinnen/Autoren geben an, dass kein Interessenkonflikt besteht., (Thieme. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
19. Diagnostics and Imaging for Pancreatic Neuroendocrine Tumors.
- Author
-
Tobias J and Keutgen XM
- Subjects
- Humans, Endosonography methods, Tomography, X-Ray Computed methods, Magnetic Resonance Imaging methods, Pancreatic Neoplasms diagnosis, Pancreatic Neoplasms diagnostic imaging, Neuroendocrine Tumors diagnosis, Neuroendocrine Tumors diagnostic imaging
- Abstract
Pancreatic neuroendocrine tumors originate from hormone-producing islet cells and have a propensity to metastasize to the liver once they reach 2 cm in size. Their diagnosis relies upon a combination of computed tomography, MRI, DOTATATE PET, and endoscopic ultrasound with or without tissue biopsy. Biochemical work-up is driven by patient symptoms of hormone excess., Competing Interests: Disclosure The authors have nothing to disclose., (Copyright © 2024 Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
20. Imaging with [ 89 Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumours of the lung and prostate: a phase 1/2, first-in-human trial.
- Author
-
Tendler S, Dunphy MP, Agee M, O'Donoghue J, Aly RG, Choudhury NJ, Kesner A, Kirov A, Mauguen A, Baine MK, Schoder H, Weber WA, Rekhtman N, Lyashchenko SK, Bodei L, Morris MJ, Lewis JS, Rudin CM, and Poirier JT
- Subjects
- Humans, Male, Middle Aged, Aged, Neuroendocrine Tumors diagnostic imaging, Neuroendocrine Tumors pathology, Neuroendocrine Tumors immunology, Neuroendocrine Tumors drug therapy, Female, Deferoxamine chemistry, Immunoconjugates pharmacokinetics, Neoplasm Grading, Radiopharmaceuticals, Adult, Antibodies, Monoclonal chemistry, Antibodies, Monoclonal administration & dosage, Aged, 80 and over, Benzodiazepinones, Antibodies, Monoclonal, Humanized, Zirconium, Membrane Proteins immunology, Membrane Proteins metabolism, Positron Emission Tomography Computed Tomography, Lung Neoplasms diagnostic imaging, Lung Neoplasms pathology, Lung Neoplasms drug therapy, Lung Neoplasms immunology, Radioisotopes, Prostatic Neoplasms diagnostic imaging, Prostatic Neoplasms pathology, Prostatic Neoplasms drug therapy, Prostatic Neoplasms immunology, Intracellular Signaling Peptides and Proteins
- Abstract
Background: Delta-like ligand 3 (DLL3) is aberrantly expressed on the surface of small-cell lung cancer (SCLC) and neuroendocrine prostate cancer cells. We assessed the safety and feasibility of the DLL3-targeted imaging tracer [
89 Zr]Zr-DFO-SC16.56 (composed of the anti-DLL3 antibody SC16.56 conjugated to p-SCN-Bn-deferoxamine [DFO] serving as a chelator for zirconium-89) in patients with neuroendocrine-derived cancer., Methods: We conducted an open-label, first-in-human study of immunoPET-CT imaging with [89 Zr]Zr-DFO-SC16.56. The study was done at Memorial Sloan Kettering Cancer Center, New York, NY, USA. Patients aged 18 years or older with a histologically verified neuroendocrine-derived malignancy and an Eastern Cooperative Oncology Group performance status of 0-2 were eligible. An initial cohort of patients with SCLC (cohort 1) received 37-74 MBq [89 Zr]Zr-DFO-SC16.56 as a single intravenous infusion at a total mass dose of 2·5 mg and had serial PET-CT scans at 1 h, day 1, day 3, and day 7 post-injection. The primary outcomes of phase 1 of the study (cohort 1) were to estimate terminal clearance half-time, determine whole organ time-integrated activity coefficients, and assess the safety of [89 Zr]Zr-DFO-SC16.56. An expansion cohort of additional patients (with SCLC, neuroendocrine prostate cancer, atypical carcinoid tumours, and non-small-cell lung cancer; cohort 2) received a single infusion of [89 Zr]Zr-DFO-SC16.56 at the same activity and mass dose as in the initial cohort followed by a single PET-CT scan 3-6 days later. Retrospectively collected tumour biopsy samples were assessed for DLL3 by immunohistochemistry. The primary outcome of phase 2 of the study in cohort 2 was to determine the potential association between tumour uptake of the tracer and intratumoural DLL3 protein expression, as determined by immunohistochemistry. This study is ongoing and is registered with ClinicalTrials.gov, NCT04199741., Findings: Between Feb 11, 2020, and Jan 30, 2023, 12 (67%) men and six (33%) women were enrolled, with a median age of 64 years (range 23-81). Cohort 1 included three patients and cohort 2 included 15 additional patients. Imaging of the three patients with SCLC in cohort 1 showed strong tumour-specific uptake of [89 Zr]Zr-DFO-SC16.56 at day 3 and day 7 post-injection. Serum clearance was biphasic with an estimated terminal clearance half-time of 119 h (SD 31). The highest mean absorbed dose was observed in the liver (1·83 mGy/MBq [SD 0·36]), and the mean effective dose was 0·49 mSv/MBq (SD 0·10). In cohort 2, a single immunoPET-CT scan on day 3-6 post-administration could delineate DLL3-avid tumours in 12 (80%) of 15 patients. Tumoural uptake varied between and within patients, and across anatomical sites, with a wide range in maximum standardised uptake value (from 3·3 to 66·7). Tumour uptake by [89 Zr]Zr-DFO-SC16.56 was congruent with DLL3 immunohistochemistry in 15 (94%) of 16 patients with evaluable tissue. Two patients with non-avid DLL3 SCLC and neuroendocrine prostate cancer by PET scan showed the lowest DLL3 expression by tumour immunohistochemistry. One (6%) of 18 patients had a grade 1 allergic reaction; no grade 2 or worse adverse events were noted in either cohort., Interpretation: DLL3 PET-CT imaging of patients with neuroendocrine cancers is safe and feasible. These results show the potential utility of [89 Zr]Zr-DFO-SC16.56 for non-invasive in-vivo detection of DLL3-expressing malignancies., Funding: National Institutes of Health, Prostate Cancer Foundation, and Scannell Foundation., Competing Interests: Declaration of interests NJC received grants from AbbVie, Amgen, Harpoon Therapeutics, Merck, Monte Rosa Therapeutics, and Roche/Genentech, royalties from Wolters Kluwer, and consulting fees from G1 Therapeutics and Sanofi, and participated on data safety and monitoring boards for AbbVie and Harpoon Therapeutics. AKe received travel support from the American Association of Physicists in Medicine and has ownership interest in patent US9814431B2. AM filed patent PCT/US2022/031066. LB declares nonremunerated consultancies for AAA-Novartis, Ipsen, Clovis, ITM, Iba, Great Point Partners, PointBiopharma, and RayzeBio; grant support from AAA-Novartis; participation on the data safety and monitoring board for AAA-Novartis, PointBiopharma, and Precirix; and the following leadership roles: Board of Directors of American Board of Nuclear Medicine and Member of the Scientific Advisory Board of the Neuroendocrine Tumor Research Foundation. MJM received honoraria from Mashup Media; declares patent application 18/448,609; has participated on data safety and monitoring boards for Lantheus, AstraZeneca, Daiichi, Convergent Therapeutics, Pfizer, ITM Isotope Technologies, Clarity Pharmaceuticals, Blue Earth Diagnostics, POINT Biopharma, Telix, Progenics, Z-Alpha, Ambrx, Flare Therapeutics, Fusion Pharmaceuticals, Curium, TransThera, Bristol Myers Squibb, Arvinas, Core Medica, Exelixis, Corcept, Janssen, Novartis, and Astellas; and has stock options in Doximity. JSL has consulted for Clarity Pharmaceuticals, Curie, Therapeutics Inc, Earli, Evergreen Theragnostics, NexTech Invest, Telix Pharmaceuticals, Suba Therapeutics, Inhibrx, Precirix, Alpha-9, Solve, and TPG Capital; a leadership role in the Society of Nuclear Medicine; stock in Curie Therapeutics, Summit Biomedical Imaging, Telix Pharmaceuticals, and Evergreen Theragnostics; and receipt of materials from Clarity Pharmaceuticals and Avid Radiopharmaceuticals. CMR has consulted for Amgen, AstraZeneca, Daiichi Sankyo, Hoffman-La Roche, Jazz, Legend, Bridge Medicines, and Harpoon Therapeutics; has a leadership role on the LUNGevity Foundation Board of Directors; and has stock options for Auron, DISCO, and Earli. JTP has consulted for GLG and DISCO. JSL, CMR, and JTP are inventors on patents WO2021007371A1, WO2022153194A, and WO2023034557A1, and have received royalty payments from Memorial Sloan Kettering Cancer Center. All other authors declare no competing interests., (Copyright © 2024 Elsevier Ltd. All rights reserved, including those for text and data mining, AI training, and similar technologies.)- Published
- 2024
- Full Text
- View/download PDF
21. Optimal follow-up with somatostatin receptor PET/CT imaging in patients with small intestinal neuroendocrine tumours.
- Author
-
Ohlsson H, Spaak E, Gålne A, Sundlöv A, and Almquist M
- Subjects
- Humans, Female, Male, Middle Aged, Aged, Follow-Up Studies, Adult, Retrospective Studies, Aged, 80 and over, Neuroendocrine Tumors diagnostic imaging, Positron Emission Tomography Computed Tomography methods, Intestinal Neoplasms diagnostic imaging, Intestinal Neoplasms pathology, Receptors, Somatostatin metabolism, Intestine, Small diagnostic imaging, Intestine, Small pathology
- Abstract
Somatostatin receptor positron emission tomography with computerised tomography imaging (SRI) has a high sensitivity for the detection of small intestinal neuroendocrine tumors (siNET), which makes it ideal for follow-up. The aim of the present study was to investigate whether follow-up with SRI in patients with siNET led to any change in the treatment of the patient and if patient and/or tumour factors were associated with such change. Adults with siNET who had undergone at least two SRI scans between 2013 and 2021 were identified. Data on age, sex, comorbidities, tumour stage, grade, and most recent levels of serum Chromogranin A (CgA) and 24-h urine 5-hydroxyindoleacetic acid (5-HIAA) before each SRI scan were obtained. The major change was defined as new treatment previously not received or discontinuation of ongoing treatment. Univariate and multivariate mixed models logistic regression on variables with a presumed biological relationship with major change and with backwards stepwise exclusion of variables with p > .1 was performed. A total of 164 patients with siNET diagnosis had undergone 570 SRI scans. The median follow-up was 3.1 years. Only 82 of 570, 14%, of SRI scans led to a major change in treatment. Female sex, age below 75 years, elevated or missing CgA, elevated or missing urine 5-HIAA, progress on last SRI scan and distant extrahepatic disease were all independently associated with increased odds ratios for major change after follow-up with SRI. A small proportion of SRI scans (14%) led to a major change in treatment. Six independent risk factors with increased odds of major change, all available before each SRI scan, were identified. While validation of these risk factors is needed in a separate cohort, these findings could help clinicians individualise follow-up for siNET patients in the future., (© 2024 The Authors. Journal of Neuroendocrinology published by John Wiley & Sons Ltd on behalf of British Society for Neuroendocrinology.)
- Published
- 2024
- Full Text
- View/download PDF
22. Synchronous duodenal neuroendocrine tumor and gastrointestinal stromal tumor: A case report.
- Author
-
Li W, Zou Q, Yin Z, and Liu W
- Subjects
- Humans, Male, Middle Aged, Female, Gastrointestinal Stromal Tumors surgery, Gastrointestinal Stromal Tumors pathology, Gastrointestinal Stromal Tumors diagnostic imaging, Gastrointestinal Stromal Tumors diagnosis, Neuroendocrine Tumors surgery, Neuroendocrine Tumors pathology, Neuroendocrine Tumors diagnosis, Neuroendocrine Tumors diagnostic imaging, Duodenal Neoplasms surgery, Duodenal Neoplasms pathology, Duodenal Neoplasms diagnostic imaging, Neoplasms, Multiple Primary surgery, Neoplasms, Multiple Primary pathology
- Abstract
Competing Interests: Declaration of competing interest The authors declared no competing interests.
- Published
- 2024
- Full Text
- View/download PDF
23. Radiologic tumor border can further stratify prognosis in patients with pancreatic neuroendocrine tumor.
- Author
-
Ahn B, Park HJ, Kim HJ, and Hong SM
- Subjects
- Humans, Male, Female, Middle Aged, Prognosis, Aged, Adult, Retrospective Studies, Aged, 80 and over, Young Adult, Pancreatic Neoplasms diagnostic imaging, Pancreatic Neoplasms pathology, Pancreatic Neoplasms surgery, Neuroendocrine Tumors diagnostic imaging, Neuroendocrine Tumors pathology, Tomography, X-Ray Computed
- Abstract
Background and Objectives: Pancreatic neuroendocrine tumor (PanNET), although rare in incidence, is increasing in recent years. Several clinicopathologic and molecular factors have been suggested for patient stratification due to the extensive heterogeneity of PanNETs. We aimed to discover the prognostic role of assessing the tumor border of PanNETs with pre-operative computed tomography (CT) images and correlate them with other clinicopathologic factors., Methods: The radiologic, macroscopic, and microscopic tumor border of 183 surgically resected PanNET cases was evaluated using preoperative CT images (well defined vs. poorly defined), gross images (expansile vs. infiltrative), and hematoxylin and eosin-stained slides (pushing vs. infiltrative). The clinicopathologic and prognostic significance of the tumor border status was compared with other clinicopathologic factors., Results: A poorly defined radiologic tumor border was observed in 65 PanNET cases (35.5 %), and were more frequent in male patients (P = 0.031), and tumor with larger size, infiltrative macroscopic growth pattern, infiltrative microscopic tumor border, higher tumor grade, higher pT category, lymph node metastasis, lymphovascular and perineural invasions (all, P < 0.001). Patients with PanNET with a poorly defined radiologic tumor border had significantly worse overall survival (OS) and recurrence-free survival (RFS; both, P < 0.001). Multivariable analysis revealed that PanNET with a poorly defined radiologic border is an independent poor prognostic factor for both OS (P = 0.049) and RFS (P = 0.027)., Conclusion: Pre-operative CT-based tumor border evaluation can provide additional information regarding survival and recurrence in patients with PanNET., Competing Interests: Declaration of competing interest The authors declare no conflict of interest., (Copyright © 2024 IAP and EPC. Published by Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
24. Endoscopic loco-regional treatment in controlling pancreatic neuroendocrine tumors (PNETs) behavior: a case series and literature review.
- Author
-
Lesmana CRA
- Subjects
- Humans, Female, Middle Aged, Male, Adult, Aged, Radiofrequency Ablation methods, Pancreatic Neoplasms diagnostic imaging, Pancreatic Neoplasms surgery, Pancreatic Neoplasms therapy, Pancreatic Neoplasms pathology, Neuroendocrine Tumors diagnostic imaging, Neuroendocrine Tumors therapy, Neuroendocrine Tumors surgery, Neuroendocrine Tumors pathology, Endosonography methods
- Abstract
Pancreatic neuroendocrine tumors (PNETs) are considered rare pancreatic neoplasms, and it is a challenging disease entity due to its indolent behavior and is difficult to manage. Diagnostic challenge is usually found in the imaging-based approach, such as transabdominal ultrasound, abdominal CT scan, and abdominal MRI. Surgery is still the main key player in controlling the disease. The main problems in clinical practice are the early detection of small PNETs lesion and non-functional PNET (NF-PNET) cases. Most cases usually come with large tumor size or metastatic disease. Endoscopic ultrasound (EUS) has been well-known as the most sensitive tool for early detection of pancreatic malignancy. It has now also been developed for managing pancreatic cancer, such as tumor ablation therapy. We presented four variety of PNETs cases (one patient with non-functioning PNETs and three patients with functioning PNETs) who have been successfully treated with EUS-guided radiofrequency ablation (RFA) with good control of tumor growth during follow-up. One patient with a large-size insulinoma could have the tumor controlled gradually after several EUS-RFA sessions. No adverse events or major complications were observed during and after the EUS-RFA procedure. EUS has been shown as a promising tool not only for more accurate diagnosis but also for tumor growth control. However, it would need further comparison studies between EUS and surgical approaches to make a better treatment strategy., (© 2024. Japanese Society of Gastroenterology.)
- Published
- 2024
- Full Text
- View/download PDF
25. The role of endoscopic ultrasonography for diagnosis of residual rectal neuroendocrine tumor.
- Author
-
Kim SJ, Lee J, Kim GW, and Kim SY
- Subjects
- Humans, Male, Female, Middle Aged, Retrospective Studies, Aged, Adult, Sensitivity and Specificity, Margins of Excision, Rectal Neoplasms diagnostic imaging, Rectal Neoplasms pathology, Rectal Neoplasms surgery, Neuroendocrine Tumors diagnostic imaging, Neuroendocrine Tumors surgery, Neuroendocrine Tumors pathology, Endosonography methods, Neoplasm, Residual diagnostic imaging, Salvage Therapy methods, Endoscopic Mucosal Resection methods
- Abstract
Background: Endoscopic ultrasonography (EUS) is useful for assessing the depth and regional lymph node involvement in rectal neuroendocrine tumors (NETs). However, evidence regarding the effectiveness of EUS in identifying residual lesions in patients with incompletely resected NET is limited. We aimed to evaluate the efficacy of EUS in identifying residual rectal NETs and the clinical outcomes of salvage endoscopic treatment., Methods: We retrospectively reviewed the records of patients who were transferred to Chosun University Hospital and received salvage treatment for incompletely resected rectal NETs between January 2012 and October 2021., Results: This study included 68 incompletely resected rectal NET, of which 59 were margin-positive and 9 were margin-indeterminate. EUS detection (odds ratio (OR), 8.44; 95% confidence interval (CI), 1.18-41.35) and visual detection (OR, 7.00; 95% CI, 1.50-47.48) were associated with residual lesion in patients with incompletely resected NET. EUS detection of residual lesions showed a sensitivity of 94%, specificity of 71%, positive predictive value of 88%, negative predictive value of 83%, and accuracy of 87%. All patients underwent salvage treatment with band-ligation endoscopic mucosal resection (58.8%) and endoscopic submucosal dissection (41.2%). Residual NETs were diagnosed in 47 of 68 patients (69.1%), and no recurrence was noted during the follow-up period of 51.8 ± 22.9 months., Conclusions: EUS is a more sensitive method than visual detection for evaluating residual rectal NETs. Salvage endoscopic treatment for incompletely resected NETs is safe and effective., (© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)
- Published
- 2024
- Full Text
- View/download PDF
26. Spleen Volume Reduction Is a Reliable and Independent Biomarker for Long-Term Risk of Leukopenia Development in Peptide Receptor Radionuclide Therapy.
- Author
-
Steinhelfer L, Jungmann F, Endrös L, Wenzel P, Haller B, Nickel M, Haneder E, Geisler F, Götze K, von Werder A, Eiber M, Makowski MR, Braren R, and Lohöfer F
- Subjects
- Humans, Female, Male, Middle Aged, Retrospective Studies, Aged, Organ Size, Adult, Biomarkers, Aged, 80 and over, Leukopenia etiology, Spleen diagnostic imaging, Spleen radiation effects, Octreotide analogs & derivatives, Octreotide therapeutic use, Octreotide adverse effects, Neuroendocrine Tumors radiotherapy, Neuroendocrine Tumors diagnostic imaging, Receptors, Peptide metabolism, Organometallic Compounds adverse effects, Organometallic Compounds therapeutic use
- Abstract
177 Lu-DOTATATE therapy is an effective treatment for advanced neuroendocrine tumors, despite its dose-limiting hematotoxicity. Herein, the significance of off-target splenic irradiation is unknown. Our study aims to identify predictive markers of peptide receptor radionuclide therapy-induced leukopenia. Methods: We retrospectively analyzed blood counts and imaging data of 88 patients with histologically confirmed, unresectable metastatic neuroendocrine tumors who received177 Lu-DOTATATE treatment at our institution from February 2009 to July 2021. Inclusion criterium was a tumor uptake equivalent to or greater than that in the liver on baseline receptor imaging. We excluded patients with less than 24 mo of follow-up and those patients who received fewer than 4 treatment cycles, additional therapies, or blood transfusions during follow-up. Results: Our study revealed absolute and relative white blood cell counts and relative spleen volume reduction as independent predictors of radiation-induced leukopenia at 24 mo. However, a 30% decline in spleen volume 12 mo after treatment most accurately predicted patients proceeding to leukopenia at 24 mo (receiver operating characteristic area under the curve of 0.91, sensitivity of 0.93, and specificity of 0.90), outperforming all other parameters by far. Conclusion: Automated splenic volume assessments demonstrated superior predictive capabilities for the development of leukopenia in patients undergoing177 Lu-DOTATATE treatment compared with conventional laboratory parameters. The reduction in spleen size proves to be a valuable, routinely available, and quantitative imaging-based biomarker for predicting radiation-induced leukopenia. This suggests potential clinical applications for risk assessment and management., (© 2024 by the Society of Nuclear Medicine and Molecular Imaging.)- Published
- 2024
- Full Text
- View/download PDF
27. Cylindrical TGR as early radiological predictor of RLT progression in GEPNETs: a proof of concept.
- Author
-
Scalorbi F, Garanzini EM, Calareso G, Marzi C, Di Rocco G, Argiroffi G, Baccini M, Pusceddu S, Marchianò A, and Maccauro M
- Subjects
- Humans, Female, Male, Middle Aged, Aged, Adult, ROC Curve, Neuroendocrine Tumors diagnostic imaging, Neuroendocrine Tumors pathology, Intestinal Neoplasms diagnostic imaging, Intestinal Neoplasms pathology, Proof of Concept Study, Tumor Burden, Disease Progression, Pancreatic Neoplasms diagnostic imaging, Pancreatic Neoplasms pathology, Stomach Neoplasms diagnostic imaging, Stomach Neoplasms pathology, Tomography, X-Ray Computed methods
- Abstract
This study aims to assess the predictive capability of cylindrical Tumor Growth Rate (cTGR) in the prediction of early progression of well-differentiated gastro-entero-pancreatic tumours after Radio Ligand Therapy (RLT), compared to the conventional TGR. Fifty-eight patients were included and three CT scans per patient were collected at baseline, during RLT, and follow-up. RLT response, evaluated at follow-up according to RECIST 1.1, was calculated as a percentage variation of lesion diameters over time (continuous values) and as four different RECIST classes. TGR between baseline and interim CT was computed using both conventional (approximating lesion volume to a sphere) and cylindrical (called cTGR, approximating lesion volume to an elliptical cylinder) formulations. Receiver Operating Characteristic (ROC) curves were employed for Progressive Disease class prediction, revealing that cTGR outperformed conventional TGR (area under the ROC equal to 1.00 and 0.92, respectively). Multivariate analysis confirmed the superiority of cTGR in predicting continuous RLT response, with a higher coefficient for cTGR (1.56) compared to the conventional one (1.45). This study serves as a proof of concept, paving the way for future clinical trials to incorporate cTGR as a valuable tool for assessing RLT response., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
28. Neoadjuvant Capecitabine Plus Temozolomide in Atypical Lung NETs.
- Author
-
Evangelou G, Vamvakaris I, Konstantopoulou I, and Syrigos K
- Subjects
- Humans, Female, Middle Aged, Neuroendocrine Tumors drug therapy, Neuroendocrine Tumors pathology, Neuroendocrine Tumors diagnostic imaging, Positron Emission Tomography Computed Tomography methods, Capecitabine administration & dosage, Capecitabine therapeutic use, Temozolomide therapeutic use, Temozolomide administration & dosage, Neoadjuvant Therapy methods, Lung Neoplasms drug therapy, Lung Neoplasms pathology, Lung Neoplasms diagnostic imaging, Antineoplastic Combined Chemotherapy Protocols therapeutic use
- Abstract
Neoadjuvant and adjuvant treatment in lung neuroendocrine tumors (NETs) is a field that has not been explored in-depth, with little information on the impact on disease-free survival. This case study highlights the effectiveness of neoadjuvant treatment with capecitabine plus temozolomide (CAPTEM) in a woman with well-differentiated atypical carcinoid. The patient was asymptomatic at diagnosis and was referred to the outpatient NET clinic at Sotiria Hospital in Athens, following an incidental finding on a chest x-ray. 18F-fluorodeoxyglucose (FDG) PET/CT and 68Ga-Dotatoc PET/CT revealed another mass in the pancreas, with avidity in both imaging studies. The patient underwent treatment for 6 months with CAPTEM with a response in the lung NET and mediastinal lymph nodes. However, the mass in the pancreas slightly increased and was removed with a central pancreatectomy. The patient continued treatment with CAPTEM for 6 more months. There was further response according to RECIST 1.1 criteria (partial response in the mediastinal lymph nodes and a 21% regression in the primary tumor size). Pathology report after lobectomy with lymph node dissection showed a pathologic complete response in the mediastinal lymph nodes. Twenty-four months after surgery, the patient remains disease-free and has a good quality of life. Although large clinical trials are needed, this case study underlines the value of preoperative chemotherapy in atypical carcinoids.
- Published
- 2024
- Full Text
- View/download PDF
29. Super Mario sign at somatostatin receptor PET/CT.
- Author
-
Usmani S, Riyami KA, Jain A, and Maraghy MA
- Subjects
- Humans, Male, Middle Aged, Radiopharmaceuticals, Organometallic Compounds, Adrenal Glands diagnostic imaging, Adrenal Glands pathology, Positron Emission Tomography Computed Tomography methods, Neuroendocrine Tumors diagnostic imaging, Neuroendocrine Tumors pathology, Receptors, Somatostatin metabolism, Stomach Neoplasms diagnostic imaging, Stomach Neoplasms pathology
- Abstract
68Ga-DOTA NOC PET-CT imaging has been shown to have high accuracy for the evaluation of neuroendocrine tumours. We present the case of a 59-year-old male with well differentiated gastric neuroendocrine tumour (grade II) treated with surgery. 68Ga-DOTA NOC PET/CT was performed to rule out metastasis. 68Ga-DOTA NOC showed physiological uptake in the bilateral adrenal and horseshoe kidney appearing as the famous character Super Mario. There is no evidence of any abnormal somatostatin avid lesion.
- Published
- 2024
- Full Text
- View/download PDF
30. [Pulmonary neuroendocrine tumors : Current review].
- Author
-
Meyer HJ, Frille A, Tiepolt S, and Denecke T
- Subjects
- Humans, Diagnosis, Differential, Tomography, X-Ray Computed, Lung Neoplasms classification, Lung Neoplasms diagnostic imaging, Lung Neoplasms pathology, Lung Neoplasms therapy, Neuroendocrine Tumors classification, Neuroendocrine Tumors diagnostic imaging, Neuroendocrine Tumors pathology, Neuroendocrine Tumors therapy
- Abstract
Clinical Issue: Neuroendocrine neoplasms of the lung are a heterogenous tumor group. The pathological classification comprises diffuse idiopathic pulmonary neuroendocrine cell hyperplasia, classic neuroendocrine tumors, and neuroendocrine carcinoma. Classic neuroendocrine tumors include typical and atypical carcinoid tumors., Diagnostic Work-Up: Imaging plays an important role in diagnosis and can help in identifying the tumor biology. Overall, this tumor group is rare, comprising less than 2% of all thoracic tumors., Practical Recommendations: In the current review, the various tumors are presented and important aspects regarding pathological classification, imaging modalities, and treatment are described., (© 2024. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature.)
- Published
- 2024
- Full Text
- View/download PDF
31. Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors: Agonist, Antagonist and Alternatives.
- Author
-
Santo G, Di Santo G, and Virgolini I
- Subjects
- Humans, Neuroendocrine Tumors radiotherapy, Neuroendocrine Tumors diagnostic imaging, Neuroendocrine Tumors metabolism, Receptors, Peptide metabolism
- Abstract
Peptide receptor radionuclide therapy (PRRT) today is a well-established treatment strategy for patients with neuroendocrine tumors (NET). First performed already more than 30 years ago, PRRT was incorporated only in recent years into the major oncology guidelines, based on its proven efficacy and safety in clinical trials. Following the phase 3 NETTER-1 trial, which led to the final registration of the radiopharmaceutical Luthatera® for G1/G2 NET patients in 2017, the long-term results of the phase 3 NETTER-2 trial may pave the way for a new treatment option also for advanced G2/G3 patients as first-line therapy. The growing knowledge about the synergistic effect of combined therapies could also allow alternative (re)treatment options for NET patients, in order to create a tailored treatment strategy. The evolving thera(g)nostic concept could be applied for the identification of patients who might benefit from different image-guided treatment strategies. In this scenario, the use of dual tracer PET/CT in NET patients, using both [
18 F]F-FDG/[68 Ga]Ga-DOTA-somatostatin analog (SSA) for diagnosis and follow-up, is under discussion and could also result in a powerful prognostic tool. In addition, alternative strategies based on different metabolic pathways, radioisotopes, or combinations of different medical approaches could be applied. A number of different promising "doors" could thus open in the near future for the treatment of NET patients - and the "key" will be thera(g)nostic!, Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 The Author(s). Published by Elsevier Inc. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF
32. Radio-Guided Surgery with a New-Generation β-Probe for Radiolabeled Somatostatin Analog, in Patients with Small Intestinal Neuroendocrine Tumors.
- Author
-
Bertani E, Mattana F, Collamati F, Ferrari ME, Bagnardi V, Frassoni S, Pisa E, Mirabelli R, Morganti S, Fazio N, Fumagalli Romario U, and Ceci F
- Subjects
- Humans, Female, Male, Prospective Studies, Middle Aged, Aged, Adult, Organometallic Compounds, Somatostatin analogs & derivatives, Follow-Up Studies, Prognosis, Beta Particles therapeutic use, Feasibility Studies, Neuroendocrine Tumors surgery, Neuroendocrine Tumors pathology, Neuroendocrine Tumors diagnostic imaging, Intestinal Neoplasms surgery, Intestinal Neoplasms pathology, Intestinal Neoplasms diagnostic imaging, Radiopharmaceuticals, Positron Emission Tomography Computed Tomography methods, Intestine, Small pathology, Intestine, Small diagnostic imaging, Intestine, Small surgery, Octreotide analogs & derivatives, Surgery, Computer-Assisted methods
- Abstract
Background: Radio-guided surgery (RGS) holds promise for improving surgical outcomes in neuroendocrine tumors (NETs). Previous studies showed low specificity (SP) using γ-probes to detect radiation emitted by radio-labeled somatostatin analogs., Objective: We aimed to assess the sensitivity (SE) and SP of the intraoperative RGS approach using a β-probe with a per-lesion analysis, while assessing safety and feasibility as secondary objectives., Methods: This prospective, single-arm, single-center, phase II trial (NCT05448157) enrolled 20 patients diagnosed with small intestine NETs (SI-NETs) with positive lesions detected at
68 Ga-DOTA-TOC positron emission tomography/computed tomography (PET/CT). Patients received an intravenous injection of 1.1 MBq/Kg of 68Ga-DOTA-TOC 10 min prior to surgery. In vivo measurements were conducted using a β-probe. Receiver operating characteristic (ROC) analysis was performed, with the tumor-to-background ratio (TBR) as the independent variable and pathology result (cancer vs. non-cancer) as the dependent variable. The area under the curve (AUC), optimal TBR, and absorbed dose for the surgery staff were reported., Results: The intraoperative RGS approach was feasible in all cases without adverse effects. Of 134 specimens, the AUC was 0.928, with a TBR cut-off of 1.35 yielding 89.3% SE and 86.4% SP. The median absorbed dose for the surgery staff was 30 µSv (range 12-41 µSv)., Conclusion: This study reports optimal accuracy in detecting lesions of SI-NETs using the intraoperative RGS approach with a novel β-probe. The method was found to be safe, feasible, and easily reproducible in daily clinical practice, with minimal radiation exposure for the staff. RGS might potentially improve radical resection rates in SI-NETs., Clinical Trials Registration:68 Ga-DOTATOC Radio-Guided Surgery with β-Probe in GEP-NET (RGS GEP-NET) [NCT0544815; https://classic., Clinicaltrials: gov/ct2/show/NCT05448157 ]., (© 2024. Society of Surgical Oncology.)- Published
- 2024
- Full Text
- View/download PDF
33. Radioligand Therapy in Patients with Lung Neuroendocrine Tumors: A Systematic Review on Efficacy and Safety.
- Author
-
Malandrino P, Feola T, Mikovic N, Cannavale G, Molfetta SD, Altieri B, Mancini C, Ferolla P, Colao A, and Faggiano A
- Subjects
- Humans, Treatment Outcome, Safety, Neuroendocrine Tumors radiotherapy, Neuroendocrine Tumors diagnostic imaging, Lung Neoplasms radiotherapy, Lung Neoplasms diagnostic imaging
- Abstract
Neuroendocrine neoplasms (NENs), arising from various sites, present therapeutic challenges. Radioligand therapy (RLT) is effective for unresectable/metastatic NENs with increased somatostatin receptor uptake. While evidence supports RLT's efficacy in midgut NETs, its role in lung NETs remains underexplored. Clinical guidelines place RLT as a third or fourth-line option in this setting. However, in the last years several studies investigated mainly retrospectively effectiveness and safety of RLT in lung NET. The aim of this review is to assess the efficacy and safety of RLT in patients with lung NETs. Following PRISMA guidelines, a systematic review of MEDLINE and EMBASE databases retrieved English articles until March 31, 2023. Inclusion criteria encompassed studies involving RLT in lung NETs with efficacy and safety assessments. Twenty-seven studies met the criteria, totaling 786 patients. The pooled analysis revealed a 25.6% objective response rate and 75.6% disease control rate. Median progression-free survival averaged 20 months, while overall survival averaged 45 months. Factors affecting response included tumor burden, prior treatments,
18 F-FDG PET scan uptake, and histological variants. RLT exhibited manageable grade 1/2 adverse effects, predominantly hematological, with Lu177 demonstrating a more favorable profile than Y90 . The findings support RLT's effectiveness in lung NETs, offering hope for advanced SSTR-positive patients. Although identifying predictive factors for response remains challenging, RLT retained efficacy even after prior therapies and typical carcinoids displayed a slightly better response than atypical ones. Prospective trials are imperative to establish RLT's definitive efficacy and its place in the therapeutic landscape for lung NETs., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 Elsevier Inc. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF
34. EANM position on positron emission tomography in suspected functional pituitary neuroendocrine tumours.
- Author
-
Van Weehaeghe D, Lapauw B, Fraioli F, Cecchin D, Verger A, Guedj E, Albert NL, Brendel M, Yakushev I, Barthel H, Traub-Weidinger T, Tolboom N, and Giessen EV
- Subjects
- Humans, Nuclear Medicine, Societies, Medical, Neuroendocrine Tumors diagnostic imaging, Pituitary Neoplasms diagnostic imaging, Positron-Emission Tomography
- Published
- 2024
- Full Text
- View/download PDF
35. Imaging of Neuroendocrine Neoplasms; Principles of Treatment Strategies. What Referring Clinicians Want to Know.
- Author
-
Asmundo L, Ambrosini V, Mojtahed A, Fanti S, Ferrone C, Hesami M, Sertic M, Najmi Z, Furtado FS, Dhami RS, Anderson MA, Samir A, Sharma A, Campana D, Ursprung S, Nikolau K, Domachevsky L, Blake MA, Norris EC, Clark JW, and Catalano OA
- Subjects
- Humans, Diagnostic Imaging methods, Referral and Consultation, Neuroendocrine Tumors diagnostic imaging, Neuroendocrine Tumors therapy
- Abstract
Abstract: Neuroendocrine neoplasms (NENs) are a diverse group of tumors that express neuroendocrine markers and primarily affect the lungs and digestive system. The incidence of NENs has increased over time due to advancements in imaging and diagnostic techniques. Effective management of NENs requires a multidisciplinary approach, considering factors such as tumor location, grade, stage, symptoms, and imaging findings. Treatment strategies vary depending on the specific subtype of NEN. In this review, we will focus on treatment strategies and therapies including the information relevant to clinicians in order to undertake optimal management and treatment decisions, the implications of different therapies on imaging, and how to ascertain their possible complications and treatment effects., Competing Interests: The authors declare no conflict of interest., (Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
36. [Imaging of neuroendocrine tumors of the gastrointestinal tract : Value of (hybrid) imaging diagnostics in radiology].
- Author
-
Ebner R, Rübenthaler J, Ricke J, Sheikh GT, Unterrainer LM, Auernhammer CJ, Spitzweg C, Brendel M, Schmid-Tannwald C, and Cyran CC
- Subjects
- Humans, Magnetic Resonance Imaging methods, Multimodal Imaging methods, Positron Emission Tomography Computed Tomography methods, Positron-Emission Tomography methods, Tomography, X-Ray Computed methods, Gastrointestinal Neoplasms diagnostic imaging, Gastrointestinal Neoplasms pathology, Gastrointestinal Neoplasms diagnosis, Neuroendocrine Tumors diagnostic imaging, Neuroendocrine Tumors pathology
- Abstract
Clinical/methodical Issue: Neuroendocrine tumors (NET) represent a heterogeneous group of rare tumors that predominantly arise in the gastrointestinal tract. At the time of initial diagnosis, the NET has already spread locoregionally in about half of the patients, and 27% of patients have already developed distant metastases. Since this plays a crucial role in therapy planning, accurate diagnostic imaging is important., Standard Radiological Methods: Due to its high temporal and spatial resolution (multiphasic including arterial phase), computed tomography (CT) plays a decisive role in primary staging and follow-up care, while magnetic resonance imaging (MRI) with its excellent soft tissue contrast offers advantages in the assessment of parenchymal organs in the upper abdomen., Methodical Innovations: Somatostatin receptor (SSR) positron emission tomography (PET) provides additional functional information that not only helps to detect the primary tumor and distant metastases, but also has a significant influence on therapeutic management in a theranostic approach., Performance: Hybrid imaging using SSR-PET/CT has proven to be particularly effective in the detection of NET. Compared to conventional imaging, it provides additional information in 68% of patients, which has a significant impact on clinical management., Achievements: Imaging of NET requires the combined use of various methods such as ultrasound, CT, MRI, and PET/CT to enable accurate diagnosis and effective treatment planning., Practical Recommendations: SSR-PET/CT is a valuable tool for the accurate staging of neuroendocrine tumors of the gastrointestinal tract, especially with small metastases, while MRI with hepatocyte-specific contrast agent and diffusion-weighted imaging is useful for the specific assessment of liver metastases., (© 2024. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature.)
- Published
- 2024
- Full Text
- View/download PDF
37. Liver Imaging in Gastroenteropancreatic Neuroendocrine Neoplasms.
- Author
-
Jeph S, Gupta S, Yedururi S, Daoud TE, Stanietzky N, and Morani AC
- Subjects
- Humans, Intestinal Neoplasms diagnostic imaging, Liver diagnostic imaging, Stomach Neoplasms diagnostic imaging, Stomach Neoplasms pathology, Neuroendocrine Tumors diagnostic imaging, Liver Neoplasms diagnostic imaging, Liver Neoplasms secondary, Pancreatic Neoplasms diagnostic imaging
- Abstract
Abstract: The incidence of neuroendocrine neoplasms (NENs) has gradually increased over the past few decades with the majority of patients presenting with metastases on initial presentation. The liver is the most common site of initial metastatic disease, and the presence of liver metastasis is an independent prognostic factor associated with a negative outcome. Because NENs are heterogenous neoplasms with variable differentiation, grading, and risk of grade transformation over time, accurate diagnosis and management of neuroendocrine liver lesions are both important and challenging. This is particularly so with the multiple liver-directed treatment options available. In this review article, we discuss the diagnosis, treatment, and response evaluation of NEN liver metastases., Competing Interests: The authors declare no conflict of interest., (Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
38. Neuroendocrine adenoma of middle ear: a case report and endoscopic approach.
- Author
-
Abrahão NM, Guimarães GC, Tamanini JB, Costa SFO, Ferreira PJM, Silva VARD, and Castilho AM
- Subjects
- Humans, Endoscopy, Neuroendocrine Tumors surgery, Neuroendocrine Tumors diagnostic imaging, Neuroendocrine Tumors pathology, Female, Tomography, X-Ray Computed, Male, Middle Aged, Ear Neoplasms surgery, Ear Neoplasms pathology, Ear Neoplasms diagnostic imaging, Ear, Middle diagnostic imaging, Ear, Middle surgery, Ear, Middle pathology, Adenoma surgery, Adenoma diagnostic imaging, Adenoma pathology
- Published
- 2024
- Full Text
- View/download PDF
39. Triple Tumors (Neuroendocrine Tumor, Schwannoma, and Papillary Thyroid Carcinoma) With Brain Lesions in a Single Patient Demonstrating Avidity on 68 Ga-DOTATATE PET/CT and Their Characterization With FDG-PET/CT and Brain MRI.
- Author
-
Parghane RV and Basu S
- Subjects
- Humans, Carcinoma, Papillary diagnostic imaging, Female, Middle Aged, Male, Multimodal Imaging, Tomography, X-Ray Computed, Brain diagnostic imaging, Brain pathology, Positron Emission Tomography Computed Tomography, Organometallic Compounds, Thyroid Cancer, Papillary diagnostic imaging, Thyroid Cancer, Papillary pathology, Thyroid Neoplasms diagnostic imaging, Thyroid Neoplasms pathology, Brain Neoplasms diagnostic imaging, Fluorodeoxyglucose F18, Magnetic Resonance Imaging, Neuroendocrine Tumors diagnostic imaging, Neuroendocrine Tumors pathology, Neurilemmoma diagnostic imaging
- Abstract
Abstract: Neuroendocrine tumor (NET) typically spreads to the liver, lymph nodes, lungs, and skeleton. Brain metastasis in NET is uncommon. Therefore, each case of detected brain metastases in NET is crucial for the development of treatment guidelines for these types of tumors. We present a unique case of triple tumors (NET, papillary thyroid carcinoma, and schwannoma) in a single patient who presented with neurological symptoms and somatostatin receptor-avid T2 hyperintense multiple metastatic brain lesions from NET on 68 Ga-DOTATATE-PET/CT scan and brain MRI. Despite the rarity of brain metastases in NET, we conclude that the presence of neurological sign or symptoms and/or the detection of somatostatin receptor-avid brain lesions in patients with NET should raise suspicion of brain metastases., Competing Interests: Conflicts of interest and sources of funding: none declared., (Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
40. Introduction to Guest Section on Neuroendocrine Tumors.
- Author
-
Tamm EP
- Subjects
- Humans, Neuroendocrine Tumors diagnostic imaging
- Published
- 2024
- Full Text
- View/download PDF
41. Relationship Between Absorbed Dose and Response in Neuroendocrine Tumors Treated with [ 177 Lu]Lu-DOTATATE.
- Author
-
Warfvinge CF, Gustafsson J, Roth D, Tennvall J, Svensson J, Bernhardt P, Åkesson A, Wieslander E, Sundlöv A, and Sjögreen Gleisner K
- Subjects
- Humans, Male, Female, Middle Aged, Retrospective Studies, Aged, Treatment Outcome, Adult, Radiometry, Radiotherapy Dosage, Single Photon Emission Computed Tomography Computed Tomography, Radiopharmaceuticals therapeutic use, Aged, 80 and over, Dose-Response Relationship, Radiation, Neuroendocrine Tumors radiotherapy, Neuroendocrine Tumors diagnostic imaging, Octreotide analogs & derivatives, Octreotide therapeutic use, Organometallic Compounds therapeutic use
- Abstract
Peptide receptor radionuclide therapy presents the possibility of tracing and quantifying the uptake of the drug in the body and performing dosimetry, potentially allowing individualization of treatment schemes. However, the details of how neuroendocrine tumors (NETs) respond to different absorbed doses are insufficiently known. Here, we investigated the relationship between tumor-absorbed dose and tumor response in a cohort of patients with NETs treated with [
177 Lu]Lu-DOTATATE. Methods: This was a retrospective study based on 69 tumors in 32 patients treated within a clinical trial. Dosimetry was performed at each cycle of [177 Lu]Lu-DOTATATE, rendering 366 individual absorbed dose assessments. Hybrid planar-SPECT/CT imaging using [177 Lu]Lu-DOTATATE was used, including quantitative SPECT reconstruction, voxel-based absorbed dose rate calculation, semiautomatic image segmentation, and partial-volume correction. Changes in tumor volume were used to determine tumor response. The volume for each tumor was manually delineated on consecutive CT scans, giving a total of 712 individual tumor volume assessments. Tumors were stratified according to grade. The relationship between absorbed dose and response was investigated using mixed-effects models and logistic regression. Tumors smaller than 4 cm3 were excluded. Results: In grade 2 NETs, a clear relationship between absorbed dose and volume reduction was observed. Our observations suggest a 90% probability of partial tumor response for an accumulated tumor-absorbed dose of at least 135 Gy. Conclusion: Our findings are in accordance with previous observations regarding the relationship between tumor shrinkage and absorbed dose. Moreover, our data suggest an absorbed dose threshold for partial response in grade 2 NETs. These observations provide valuable insights for the design of dosimetry-guided peptide receptor radionuclide therapy schemes., (© 2024 by the Society of Nuclear Medicine and Molecular Imaging.)- Published
- 2024
- Full Text
- View/download PDF
42. Preoperative assessment of lymph nodal metastases with [ 68 Ga]Ga-DOTATOC PET radiomics for improved surgical planning in well-differentiated pancreatic neuroendocrine tumours.
- Author
-
Mapelli P, Bezzi C, Muffatti F, Ghezzo S, Canevari C, Magnani P, Schiavo Lena M, Battistella A, Scifo P, Andreasi V, Partelli S, Chiti A, Falconi M, and Picchio M
- Subjects
- Humans, Female, Middle Aged, Male, Aged, Adult, Image Processing, Computer-Assisted methods, Positron Emission Tomography Computed Tomography methods, Positron-Emission Tomography methods, Preoperative Period, Radiomics, Pancreatic Neoplasms diagnostic imaging, Pancreatic Neoplasms surgery, Pancreatic Neoplasms pathology, Neuroendocrine Tumors diagnostic imaging, Neuroendocrine Tumors pathology, Neuroendocrine Tumors surgery, Octreotide analogs & derivatives, Lymphatic Metastasis diagnostic imaging, Organometallic Compounds
- Abstract
Purpose: Accurate identification of lymph node (LN) metastases is pivotal for surgical planning of pancreatic neuroendocrine tumours (PanNETs); however, current imaging techniques have sub-optimal diagnostic sensitivity. Aim of this study is to investigate whether [
68 Ga]Ga-DOTATOC PET radiomics might improve the identification of LN metastases in patients with non-functioning PanNET (NF-PanNET) referred to surgical intervention., Methods: Seventy-two patients who performed preoperative [68 Ga]Ga-DOTATOC PET between December 2017 and March 2022 for NF-PanNET. [68 Ga]Ga-DOTATOC PET qualitative assessment of LN metastases was measured using diagnostic balanced accuracy (bACC), sensitivity (SN), specificity (SP), positive and negative predictive values (PPV, NPV). SUVmax, SUVmean, Somatostatin receptor density (SRD), total lesion SRD (TLSRD) and IBSI-compliant radiomic features (RFs) were obtained from the primary tumours. To predict LN involvement, these parameters were engineered, selected and used to train different machine learning models. Models were validated using tenfold repeated cross-validation and control models were developed. Models' bACC, SN, SP, PPV and NPV were collected and compared (Kruskal-Wallis, Mann-Whitney)., Results: LN metastases were detected in 29/72 patients at histology. [68 Ga]Ga-DOTATOC PET qualitative examination of LN involvement provided bACC = 60%, SN = 24%, SP = 95%, PPV = 78% and NPV = 65%. The best-performing radiomic model provided a bACC = 70%, SN = 77%, SP = 61%, PPV = 60% and NPV = 83% (outperforming the control model, p < 0.05*)., Conclusion: In this study, [68 Ga]Ga-DOTATOC PET radiomics allowed to increase diagnostic sensitivity in detecting LN metastases from 24 to 77% in NF-PanNET patients candidate to surgery. Especially in case of micrometastatic involvement, this approach might assist clinicians in a better patients' stratification., (© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)- Published
- 2024
- Full Text
- View/download PDF
43. Clinical Intricacies and Advances in Neuroendocrine Tumors: An Organ-Based Multidisciplinary Approach.
- Author
-
Asmundo L, Ambrosini V, Anderson MA, Fanti S, Bradley WR, Campana D, Mojtahed A, Chung R, Mcdermott S, Digumarthy S, Ursprung S, Nikolau K, Fintelmann FJ, Blake M, Fernandez-Del Castillo C, Qadan M, Pandey A, Clark JW, and Catalano OA
- Subjects
- Humans, Neuroendocrine Tumors diagnostic imaging, Neuroendocrine Tumors therapy, Neuroendocrine Tumors pathology
- Abstract
Abstract: Neuroendocrine neoplasms (NENs) are rare neoplasms originating from neuroendocrine cells, with increasing incidence due to enhanced detection methods. These tumors display considerable heterogeneity, necessitating diverse management strategies based on factors like organ of origin and tumor size. This article provides a comprehensive overview of therapeutic approaches for NENs, emphasizing the role of imaging in treatment decisions. It categorizes tumors based on their locations: gastric, duodenal, pancreatic, small bowel, colonic, rectal, appendiceal, gallbladder, prostate, lung, gynecological, and others. The piece also elucidates the challenges in managing metastatic disease and controversies surrounding MEN1-neuroendocrine tumor management. The article underscores the significance of individualized treatment plans, underscoring the need for a multidisciplinary approach to ensure optimal patient outcomes., Competing Interests: The authors declare no conflict of interest., (Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
44. Alpha-emitter Peptide Receptor Radionuclide Therapy in Neuroendocrine Tumors.
- Author
-
Bhimaniya S, Shah H, and Jacene HA
- Subjects
- Humans, Octreotide analogs & derivatives, Octreotide therapeutic use, Radioisotopes therapeutic use, Neuroendocrine Tumors radiotherapy, Neuroendocrine Tumors diagnostic imaging, Radiopharmaceuticals therapeutic use, Alpha Particles therapeutic use, Receptors, Peptide
- Abstract
Peptide receptor radionuclide therapy (PRRT) has become mainstream therapy of metastatic neuroendocrine tumors not controlled by somatostatin analog therapy. Currently, beta particle-emitting radiopharmaceuticals are the mainstay of PRRT. Alpha particle-emitting radiopharmaceuticals have a theoretic advantage over beta emitters in terms of improved therapeutic efficacy due to higher cancer cell death and lower nontarget tissue radiation-induced adverse events due to shorter path length of alpha particles. We discuss the available evidence for and the role of alpha particle PRRT., Competing Interests: Disclosure S. Bhimaniya and H. Shah have no disclosure. H.A. Jacene has research support: Blue Earth Diagnostics, Inc; Lantheus Consulting: Advanced Accelerator Applications, Spectrum Dynamics Royalties: Cambridge Publishing; Honoraria: Blue Earth Diagnostics, Inc., Munrol., (Copyright © 2024 Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
45. Beta Probe for Radioguided Surgery in Gastrointestinal Neuroendocrine Tumors: A Move in the Right Direction.
- Author
-
Kebebew E
- Subjects
- Humans, Surgery, Computer-Assisted methods, Neuroendocrine Tumors surgery, Neuroendocrine Tumors diagnostic imaging, Neuroendocrine Tumors pathology, Gastrointestinal Neoplasms surgery, Gastrointestinal Neoplasms pathology, Gastrointestinal Neoplasms diagnostic imaging, Radiopharmaceuticals
- Published
- 2024
- Full Text
- View/download PDF
46. Improvements and future perspective in diagnostic tools for neuroendocrine neoplasms.
- Author
-
Massironi S, Franchina M, Ippolito D, Elisei F, Falco O, Maino C, Pagni F, Elvevi A, Guerra L, and Invernizzi P
- Subjects
- Humans, Positron-Emission Tomography, Early Detection of Cancer methods, Precision Medicine, Magnetic Resonance Imaging methods, High-Throughput Nucleotide Sequencing, Artificial Intelligence, Neuroendocrine Tumors diagnosis, Neuroendocrine Tumors genetics, Neuroendocrine Tumors diagnostic imaging
- Abstract
Introduction: Neuroendocrine neoplasms (NENs) represent a complex group of tumors arising from neuroendocrine cells, characterized by heterogeneous behavior and challenging diagnostics. Despite advancements in medical technology, NENs present a major challenge in early detection, often leading to delayed diagnosis and variable outcomes. This review aims to provide an in-depth analysis of current diagnostic methods as well as the evolving and future directions of diagnostic strategies for NENs., Area Covered: The review extensively covers the evolution of diagnostic tools for NENs, from traditional imaging and biochemical tests to advanced genomic profiling and next-generation sequencing. The emerging role of technologies such as artificial intelligence, machine learning, and liquid biopsies could improve diagnostic precision, as could the integration of imaging modalities such as positron emission tomography (PET)/magnetic resonance imaging (MRI) hybrids and innovative radiotracers., Expert Opinion: Despite progress, there is still a significant gap in the early diagnosis of NENs. Bridging this diagnostic gap and integrating advanced technologies and precision medicine are crucial to improving patient outcomes. However, challenges such as low clinical awareness, limited possibility of noninvasive diagnostic tools and funding limitations for rare diseases like NENs are acknowledged.
- Published
- 2024
- Full Text
- View/download PDF
47. Neuroendocrine Tumors: Diagnostics.
- Author
-
Sakellis C and Jacene HA
- Subjects
- Humans, Positron-Emission Tomography methods, Radiopharmaceuticals, Positron Emission Tomography Computed Tomography methods, Neuroendocrine Tumors diagnostic imaging, Receptors, Somatostatin metabolism
- Abstract
Neuroendocrine neoplasms (NEN) are rare tumors arising from neuroendocrine cells. NEN are ideally suited for a theragnostic approach due to their specific expression of somatostatin receptors (SSTR). SSTR imaging of NEN dates back to the 1980s, but has evolved recently due to the introduction of more sensitive SSTR PET radiotracers. SSTR PET is a primary imaging modality for identifying NEN and characterizing SSTR expression. SSTR PET is complementary to anatomic imaging for assessing tumor response to treatment. SSTR PET is mandated to determine eligibility for peptide receptor radionuclide therapy. Here, the role of imaging to aid management of NEN is reviewed., Competing Interests: Disclosure C. Sakellis: Nothing to disclose. H.A. Jacene: Research support: Blue Earth Diagnostics, Inc., Lantheus; Consulting: Advanced Accelerator Applications, Spectrum Dynamics, Royalties: Cambridge Publishing; Honararia: Blue Earth Diagnostics, Inc, Monrol., (Copyright © 2024 Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
48. Safety and Efficacy of 177 Lu-DOTATATE in Children and Young Adult Population : A Single-Center Experience.
- Author
-
Aggarwal P, Satapathy S, Sood A, Singh H, Mittal BR, Lal S, Gupta R, Das CK, Yadav TD, and Walia R
- Subjects
- Humans, Adolescent, Male, Adult, Female, Young Adult, Child, Retrospective Studies, Treatment Outcome, Safety, Organometallic Compounds adverse effects, Organometallic Compounds therapeutic use, Neuroendocrine Tumors radiotherapy, Neuroendocrine Tumors diagnostic imaging, Neuroendocrine Tumors drug therapy, Octreotide analogs & derivatives, Octreotide adverse effects, Octreotide therapeutic use
- Abstract
Purpose: This single-center retrospective study explores the safety and efficacy of 177 Lu-DOTATATE in children and young adult population with metastatic/inoperable neuroendocrine tumors (NETs)., Patients and Methods: This study is a retrospective analysis of all children and young adult patients (≤29 years) with advanced inoperable/metastatic epithelial or nonepithelial NETs who were administered a median of 4 cycles of 177 Lu-DOTATATE therapy and low-dose oral capecitabine as a radiosensitizer every 8-12 weeks, except 2 patients who received CAPTEM chemotherapy. The radiological response was assessed using RECIST 1.1 on interim and end-of-treatment 68 Ga-DOTANOC PET/CT. The primary endpoint was objective response rate, whereas disease control rate, toxicity profile, progression-free survival, and overall survival were secondary endpoints., Results: Nineteen biopsy-proven NET patients (median age, 22 ± 10 years) with 8 of them adolescents (10-18 years) and the remaining young adults (19-29 years) were included. Fourteen patients had gastroenteropancreatic neuroendocrine tumor (pancreas being most common primary site), whereas the rest had non-gastroenteropancreatic neuroendocrine tumor. A total of 65 cycles of 177 Lu-DOTATATE (range, 1-6 cycles) were administered with a median cumulative activity of 600 mCi (range, 100-1000 mCi). The objective response rate and disease control rate were 41% and 94%, respectively. Grade 1 and 2 adverse events were observed in 14 (74%) and 5 (26%) of 19 patients, respectively. In a total of 8 events (42%), 4 events each of disease progression and death occurred during a median follow-up of 80.1 months with an estimated 5-year progression-free survival and overall survival of 54% (95% confidence interval, 30-78) and 63% (95% confidence interval, 39-87), respectively., Conclusions: 177 Lu-DOTATATE appears safe and effective in children and young adults with metastatic/inoperable NETs. Large prospective trials are required to validate these results., Competing Interests: Conflicts of interest and sources of funding: none declared., (Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
49. State-of-the-Art Hybrid Imaging of Neuroendocrine Neoplasms.
- Author
-
Ambrosini V, Fortunati E, Fanti S, Ursprung S, Asmundo L, O'Shea A, Kako B, Lee S, Furtado FS, Blake M, Goiffon RJ, Najmi Z, Hesami M, Murakami T, Domachevsky L, and Catalano OA
- Subjects
- Humans, Multimodal Imaging methods, Magnetic Resonance Imaging methods, Neuroendocrine Tumors diagnostic imaging, Positron Emission Tomography Computed Tomography methods, Radiopharmaceuticals
- Abstract
Abstract: Neuroendocrine neoplasms (NENs) may be challenging to diagnose due to their small size and diverse anatomical locations. Hybrid imaging techniques, specifically positron emission tomography/computed tomography (PET/CT) and positron emission tomography/magnetic resonance imaging (PET/MRI), represent the current state-of-the-art for evaluating NENs. The preferred radiopharmaceuticals for NEN PET imaging are gallium-68 (68Ga) DOTA-peptides, which target somatostatin receptors (SSTR) overexpressed on NEN cells. Clinical applications of [68Ga]Ga-DOTA-peptides PET/CT include diagnosis, staging, prognosis assessment, treatment selection, and response evaluation. Fluorodeoxyglucose-18 (18F-FDG) PET/CT aids in detecting low-SSTR-expressing lesions and helps in patient stratification and treatment planning, particularly in grade 3 neuroendocrine tumors (NETs). New radiopharmaceuticals such as fluorine-labeled SSTR agonists and SSTR antagonists are emerging as alternatives to 68Ga-labeled peptides, offering improved detection rates and favorable biodistribution. The maturing of PET/MRI brings advantages to NEN imaging, including simultaneous acquisition of PET and MRI images, superior soft tissue contrast resolution, and motion correction capabilities. The PET/MRI with [68Ga]Ga-DOTA-peptides has demonstrated higher lesion detection rates and more accurate lesion classification compared to PET/CT. Overall, hybrid imaging offers valuable insights in the diagnosis, staging, and treatment planning of NENs. Further research is needed to refine response assessment criteria and standardize reporting guidelines., Competing Interests: The authors declare no conflict of interest., (Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
50. Determinants of the uptake of the uncinate process of pancreas in 68 Ga-DOTATOC PET/CT: a retrospective study.
- Author
-
Jallet L, Othmani W, Perrier M, and Morland D
- Subjects
- Humans, Male, Female, Retrospective Studies, Middle Aged, Aged, Adult, Neuroendocrine Tumors diagnostic imaging, Neuroendocrine Tumors metabolism, Aged, 80 and over, Positron Emission Tomography Computed Tomography methods, Octreotide analogs & derivatives, Pancreas diagnostic imaging, Pancreas metabolism, Organometallic Compounds
- Abstract
Purpose: an increased uptake of the uncinate process of pancreas (UPP) has been described in about one-third of somatostatin receptor imaging procedures and may hinder image interpretation. The determinants of this uptake are however poorly understood. The aim of this study was to investigate the impact of cold somatostatin analogues (cSA) on UPP
68 Ga-DOTATOC uptake. Age and diabetic status were also studied., Methods: all adult patients who performed a68 Ga-DOTATOC PET/CT in our center between May 2021 and April 2023 were retrospectively screened. For each one, UPP uptake was visually assessed and measured using SUVmax. Clinical data including cSA medication, age and diabetic status were collected. Univariate and multivariate analyses were conducted using logistic regression. SUVmax comparisons were conducted using a Mann-Whitney Wilcoxon test., Results: 82 patients were included. UPP uptake was significantly lower in patients treated with cSA (OR 0.27, p = 0.015 in multivariate analysis), with a lower SUVmax (4.97 vs. 8.81, p = 0.001). No significant result was found regarding diabetic status or age., Conclusion: cold somatostatin analog treatment decreased the physiological UPP uptake in68 Ga-DOTATOC PET/CT. This effect could be used to reduce interpretation errors in this location., (© 2023. The Author(s).)- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.